IBIO supply chain intelligence for iBio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
iBio, Inc. (IBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RUBRYC | RUBRYC | 92% | iBio also entered into a Stock Purchase Agreement with RubrYc whereby we purchased 1,909,563 shares of RubrYc's Series A-2 preferred stock |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candida… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| SKYE | Skye Bioscience, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| SKYE | Skye Bioscience, Inc. | 72% | Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeut… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST g… |
| TWST | Twist Bioscience Corporation | 72% | as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. Our research and development activities take place primarily at our facilities in … |
| VKTX | Viking Therapeutics, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE grap… |
| WVE | Wave Life Sciences Ltd. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any o… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of … |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMYMP | Bristol-Myers Squibb Co | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any… |
| CLDX | Celldex Therapeutics, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the … |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the … |
| GILD | Gilead Sciences, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| JNJ | Johnson & Johnson | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any o… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: icantly more experience commercializi… |
| LLY | Eli Lilly and Company | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| MRK | Merck & Co., Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| TWST | Twist Bioscience Corporation | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any o… |
| VKTX | Viking Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BRYAN-CAPITAL-INVESTORS-LLC | BRYAN-CAPITAL-INVESTORS-LLC | 62% | eration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) we paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under t… |
| CDMO-LLC | CDMO-LLC | 62% | pany does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023. Conc… |
| CHARDAN-CAPITAL-MARKETS-LLC | CHARDAN-CAPITAL-MARKETS-LLC | 62% | range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, … |
| CO-LLC | CO-LLC | 62% | r elects to accelerate the maturity of the 2024 Term Note, the entire principal remaining unpaid hereunder shall thereafter bear interest at the rate equal to the Effective Rate plus 6% per annum . … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IBIO-DEBT-10165 | Warrants outstanding: 9595002 | 90% | xbrl warrant detail from xbrl 2024-06-30. |
| IBIO-DEBT | Debt stack $2.3M | 90% | Market cache reports total debt of $2.3M. |
| IBIO-DEBT-10166 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-06-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IBIO-OWNER-AFFINITY-ASSET-ADVISORS-LLC | Affinity Asset Advisors, LLC | 90% | 13F overlay lists Affinity Asset Advisors, LLC as top holder; 53 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 |